Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Metrics to compare | ETON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETONPeersSector | |
|---|---|---|---|---|
P/E Ratio | −159.9x | −5.8x | −0.5x | |
PEG Ratio | 10.10 | 0.11 | 0.00 | |
Price / Book | 28.1x | 0.7x | 2.6x | |
Price / LTM Sales | 9.2x | 1.5x | 3.2x | |
Upside (Analyst Target) | 29.9% | 109.6% | 47.6% | |
Fair Value Upside | Unlock | 12.5% | 6.1% | Unlock |